Clinical trials
Thrombocytopenia clinical trials
Below are recruiting thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06686927RecruitingPhase 2
Steroids, IVIG, and romiplostim for severe ITP
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Wuhan, HubeiAges 18–75 - NCT06722586RecruitingPhase 4
Sirolimus alone for low platelet counts from antiphospholipid antibodies
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
Changsha, HunanAges 18 years+ - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT06787989RecruitingPhase 1
BCMA-CD19 car T cell therapy for immune thrombocytopenia with autoimmune diseases
This trial tests a personalized cell therapy (CAR T cells) that targets two proteins (BCMA and CD19) on immune cells to treat low platelet counts (thrombocytopenia) that haven't improved with other treatments and are linked to autoimmune diseases like lupus or Sjogren's. The goal is to see if this therapy can safely raise your platelet levels and reduce bleeding symptoms.
Chengdu, SichuanAges 18–60 - NCT06788691RecruitingPhase 2
Luspatercept for low blood counts with gene change (CCUS)
This trial tests a drug called luspatercept for people with a condition called CCUS, where they have low blood counts and a gene change. The goal is to see if the drug can improve blood counts and reduce symptoms like fatigue or bleeding risk.
New York, New YorkAges 18 years+ - NCT06809101Recruiting
Home blood test monitoring for cancer patients on chemotherapy
This study tests whether cancer patients can do their own blood counts at home using a finger-prick test. It will help see if home monitoring is a good option for people receiving chemotherapy.
Næstved, Region SjællandAges 18 years+ - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06943937RecruitingPhase 1
Cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT07048249RecruitingEarly Phase 1
Romiplostim to prevent low platelets in Ewing sarcoma
This trial tests a platelet-boosting medicine called romiplostim to prevent dangerously low platelet counts caused by chemotherapy in children with newly diagnosed Ewing sarcoma. It is designed for patients who do not have cancer spread to the bone marrow and have not taken similar platelet drugs before.
Phoenix, ArizonaAges 1 year+ - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07093606Recruiting
Eltrombopag and liver function in ITP patients
This study looks at how the drug eltrombopag affects the liver in people with primary ITP (immune thrombocytopenic purpura), a condition where the immune system destroys platelets. It aims to check if liver problems develop during treatment and who might be at higher risk.
SohagAges 18–75 - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07230067Recruiting
Sepsis with low platelets: platelet transfusion study
This study looks at whether platelet transfusions help patients with sepsis and very low platelet counts recover better. If you or your loved one had sepsis, a low platelet count, and were in the ICU for at least two days, this trial may be relevant.
Guangzhou, GuangdongAges 18 years+ - NCT07257809RecruitingPhase 2
Herombopag for low platelets from T-DM1 in breast cancer
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
Guangzhou, GuangdongAges 18–75 - NCT07290634Recruiting
Comparing blood-clotting medicines for trauma patients needing many transfusions
This trial looks at two medicines (PCC and recombinant activated Factor VIIa) that help blood clot, to see which works better for trauma patients who need a lot of blood transfusions. If you have a severe injury and need many blood transfusions quickly, this study may help identify the best treatment.
Jacksonville, FloridaAges 18 years+ - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07394153RecruitingPhase 2
Testing pacritinib for myelofibrosis patients with low platelets
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
Barcelona, BarcelonaAges 18 years+ - NCT02720679Recruiting
Study genetics behind blood disorders in children and families
This study looks at genetic (DNA) factors that may contribute to certain blood disorders. You may be invited if you or a close family member is receiving care for a blood condition like MDS or MPN, and the study also includes related relatives.
Memphis, TennesseeAges Any age - NCT07442513RecruitingPhase 3
Preventing Bleeding in Stem Cell Transplant
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Hangzhou, ZhejiangAges 18–70
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombocytopenia?
- Yes. Clin2 currently lists 147 recruiting thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.